Accuronix is a small pharma company developing drugs for cancer therapy. Founded by 2 faculty members at Wash Univ in St. Louis, Accuronix has an exclusive license for our lead molecule, ACXT-3102, in preclinical development. ACXT-3102 is a drug conjugate with 2 functional domains: a sigma-2 ligand-based delivery domain facilitating efficient internalization, and an effector domain that inhibits the cystine-glutamate antiporter and prevents uptake of vital precursors needed to defend the cells from oxidative stress/death. The molecule targets cancer cells overexpressing the sigma-2 receptor and is quickly taken up into cells. ACXT-3102d is highly water soluble and administered orally for preclinical safety/pharmacology studies. The company was awarded an STTR Phase II grant to facilitate preclinical development. 1 kg of ACXT-3102d was made to support the preclinical program. Accuronix’s primary clinical focus is pancreatic adenocarcinoma and is targeting an IND submission by mid-2025.